Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cimetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.62 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ATP4A | P20648 | 1/20 | 0.62 |
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ATP4B | P51164 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cimetidine SCHEMBL2873984 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL1163516 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL1093 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10859058 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL2873981 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10855569 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL10855575 | 0.95 | SLC47A1 (0.69) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL7110586 | 0.94 | SLC47A1 (0.67) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL8159640 | 0.94 | SLC47A1 (0.67) | HRH2SLC47A1MEN1SLC22A2LMNA | |
| Cimetidine SCHEMBL7192768 | 0.94 | SLC47A1 (0.67) | HRH2SLC47A1MEN1SLC22A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118290348-A | Synthesis method of 4-chloropyrrolo pyrimidine compound or derivative thereof | 诚达药业股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-116963744-A | Pharmaceutical, therapeutic combination and method for preventing viral and microbial infections and their sequelae | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2023-10-27 | — | — | CN | claimed |
| CN-111499622-B | Preparation method of medicine for treating bile duct cancer | 山东省科学院菏泽分院 | 2023-06-06 | — | — | CN | claimed |
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | WEIDNER MORTEN SLOTH (DK) | 2003-08-21 | — | — | US | claimed |
| WO-2003045359-A2 | COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER | ASTION ONCOLOGY APS (DK) | 2003-06-05 | — | — | WO | claimed |
| CN-118290348-A | Synthesis method of 4-chloropyrrolo pyrimidine compound or derivative thereof | 诚达药业股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-115803326-B | EGFR inhibitor, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116963744-A | Pharmaceutical, therapeutic combination and method for preventing viral and microbial infections and their sequelae | 拓比利亚欧斯特有限公司(ACN 652 771 670) | 2023-10-27 | — | — | CN | disclosed |
| CN-113480548-B | Preparation method of 4-aminopyrrolo [2,1-f ] [1,2,4] triazine | 山东三牧新材料科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-111499622-B | Preparation method of medicine for treating bile duct cancer | 山东省科学院菏泽分院 | 2023-06-06 | — | — | CN | disclosed |
| CN-111499622-B | Preparation method of medicine for treating bile duct cancer | 山东省科学院菏泽分院 | 2023-06-06 | — | — | CN | disclosed |
| CN-111777593-A | Novel compounds as inhibitors of rearrangement kinase during transfection | 南京天印健华医药科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| EP-0257823-B1 | PHARMACEUTICAL FORMULATIONS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-05-06 | — | — | EP | disclosed |
| US-4996222-A | Cimetidine in crystal form | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-02-26 | — | — | US | disclosed |
| EP-0257823-A1 | Pharmaceutical formulations | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-03-02 | — | — | EP | disclosed |
| WO-1988000825-A1 | PHARMACEUTICAL FORMULATIONS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158118-A1 | Combination of cimetidine and cysteine derivatives for treating cancer | MGMT, CMA1, CYSLTR2 | HRH2 4/4885SLC47A1 274/4885MEN1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.